BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25989631)

  • 61. Performance goals for immunoglobulins and serum free light chain measurements in plasma cell dyscrasias can be based on biological variation.
    Hansen CT
    Clin Chem Lab Med; 2016 Jun; 54(6):1031-3. PubMed ID: 26824979
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The utility of the serum heavy/light chain assay as a complementary tool in the monitoring of patients with plasma cell myeloma: a report of three cases.
    Kim H; Lee JK; Hong YJ; Hong SI; Shin DY; Kang HJ; Chang YH
    Ann Clin Lab Sci; 2015; 45(2):193-8. PubMed ID: 25887874
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Clinical usefulness of serum free light chain measurement in monoclonal gammopathy].
    Shimazaki C; Murakami H; Sawamura M; Matsuda M; Kinoshita T; Hata H; Sugiura I; Tsushita K; Nagura E; Kosugi H; Itoh J; Shimizu K
    Rinsho Ketsueki; 2010 Apr; 51(4):245-52. PubMed ID: 20467220
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Benign and malignant monoclonal gammopathies.
    Carney DN; Bunn PA
    Prim Care; 1980 Sep; 7(3):369-94. PubMed ID: 6777792
    [No Abstract]   [Full Text] [Related]  

  • 65. Analytical Criticalities Associated to Different Immunological Methods for Serum Free Light Chain Detection in Plasma Cell Dyscrasias: A Description of Particular Clinical Cases.
    Sabatino R; Perrone A; Cuomo M; Liotti S; Barchiesi V; Cantile M; Cavalcanti E
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417905
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Monoclonal gammopathies. I. Distribution of heavy and light chain types in 182 patients (author's transl)].
    Ruiz-Reyes G; Landero de Ruiz N; Armenta Olvera T; Fernández MS; Pérez de Sánchez CL; Ojeda IG
    Rev Invest Clin; 1978; 30(4):359-65. PubMed ID: 102016
    [No Abstract]   [Full Text] [Related]  

  • 67. IgD paraproteinemias.
    Tichý M; Matĕja F; Urban P; Matuska M
    Neoplasma; 1993; 40(1):59-61. PubMed ID: 8350950
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Disorders of immunoglobulins with abnormal molecular structures-immunoglobulin fragment disease].
    Imamura Y
    Rinsho Ketsueki; 1975 Nov; 16(11):1007-35. PubMed ID: 814356
    [No Abstract]   [Full Text] [Related]  

  • 69. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Sixth International Symposium on clinical applications of serum free light chain analysis, Bath, England, 23-24 September 2010].
    Decaux O
    Rev Med Interne; 2011 Jan; 32(1):64-6. PubMed ID: 21126805
    [No Abstract]   [Full Text] [Related]  

  • 71. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.
    Boyle EM; Fouquet G; Guidez S; Bonnet S; Demarquette H; Dulery R; Herbaux C; Noel MP; Manier S; Schraen S; Onraed B; Faucompré JL; Hennache B; Petillon MO; Mathiot C; Avet-Loiseau H; Facon T; Harding SJ; Moreau P; Leleu X
    Cancer; 2014 Dec; 120(24):3952-7. PubMed ID: 25116271
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Free light-chains and renal disorders: when small is worse.
    Stratta P; Airoldi A; Izzo C; Rossi D; Gaidano GL
    Lancet; 2010 Oct; 376(9748):1221; author reply 1221-2. PubMed ID: 20934589
    [No Abstract]   [Full Text] [Related]  

  • 73. The spectrum of monoclonal immunoglobulin deposition disease associated with immunocytic dyscrasias.
    Gallo G; Picken M; Buxbaum J; Frangione B
    Semin Hematol; 1989 Jul; 26(3):234-45. PubMed ID: 2506646
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease.
    Levinson SS
    Clin Chem Lab Med; 2016 Jun; 54(6):1039-43. PubMed ID: 26368046
    [TBL] [Abstract][Full Text] [Related]  

  • 75. IgE lambda monoclonal gammopathy and amyloidosis.
    Jako JM; Gesztesi T; Kaszas I
    Int Arch Allergy Immunol; 1997 Apr; 112(4):415-21. PubMed ID: 9104800
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias.
    Willrich MA; Katzmann JA
    Clin Chem Lab Med; 2016 Jun; 54(6):907-19. PubMed ID: 26509779
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Biological variation of immunoglobulin heavy chain-light chain pairs in serum.
    Finlay JA; Wu AH
    Clin Chim Acta; 2014 Sep; 436():68-71. PubMed ID: 24824555
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The evolving use of serum free light chain assays in haematology.
    Pratt G
    Br J Haematol; 2008 May; 141(4):413-22. PubMed ID: 18318757
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Current role of the laboratory in the demonstration and follow up of monoclonal immunoglobulinopathy].
    Myara I
    Pathol Biol (Paris); 1990 Feb; 38(2):134-43. PubMed ID: 2107510
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Diagnostic significance of kappa/lambda and lambda/kappa ratio in paraproteinemias.
    Tichý M; Hrncír Z
    Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl; 1982; 25(3-4):313-8. PubMed ID: 6820852
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.